Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maureen Riordan

Senior Deals Analyst

Connecticut, US
Maureen has been with Strategic Transactions for 20 years, first as a Research Analyst, now as a Senior Deals Analyst, with a brief in-between stint as Editor/Contributor for Start-Up company profiles. In her current role, she primarily researches, analyzes, writes, and edits summaries involving current biopharma and medtech deals – which appear in the ST database and the monthly dealmaking section of In Vivo – and also writes and updates legacy deals. Maureen regularly co-authors a quarterly statistics column covering deal trends in both the biopharma and medtech industries for In Vivo. Prior to joining Strategic Transactions, Maureen was a corporate librarian in a management consulting firm fielding search requests for in-house analysts, and then spent two years with Lexis-Nexis as a customer consultant having daily contact with client subscribers to teach database searching techniques. Maureen holds a Bachelor of Arts degree in English from Niagara University, and a Master of Library Science degree from Southern Connecticut State University.

Latest From Maureen Riordan

Deals In Depth: August 2020

Biogen and Denali entered into a potential $2.15bn alliance for Denali’s DNL151 for Parkinson’s disease and other neurodegenerative diseases. Siemens Healthineers announced plans to acquire Varian Medical for $16.4bn. Financing reached $7.9bn in biopharma, $501m in device, and $639m in diagnostics.

BioPharmaceutical Medical Device

Deals In Depth: July 2020

Daiichi Sankyo partnered its Phase I DS-1062 for non-small cell lung cancer and triple negative breast cancer with AstraZeneca in a deal that could be worth up to $6bn. Medtronic entered into an agreement to acquire Medicrea in an all-cash tender offer for total consideration of approximately $228m (including approximately $57M of net cash and liabilities). Financing reached $11.7bn in biopharma, $1.4bn in device, and $597m in diagnostics.

Deals Market Intelligence

Dealmaking Quarterly Statistics, Q2 2020

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Deals BioPharmaceutical

Financing Quarterly Statistics, Q2 2020

During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.

Deals Market Intelligence

Deals In Depth: June 2020

Genmab and AbbVie penned a broad oncology collaboration worth up to $3.9bn. Novo Nordisk entered into an agreement to acquire Corvidia Therapeutics for $725m up front in cash and up to $1.375bn in earn-outs.

Deals Market Intelligence

Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2020

Device financing totaled $1.4bn during the first quarter of 2020. Merger and acquisition activity reached $714.5m, with only two transactions hitting the six-figure mark. Financings by diagnostics/research players totaled $985m and just six companies were acquired, four of which together were valued at $11.6bn, most coming from Thermo Fisher Scientific’s $11.5bn buy of fellow public life sciences company Qiagen NV.

Deals Market Intelligence
See All
UsernamePublicRestriction

Register